Linker ID	LIN0KSFFF
Linker Name	PEG-pAB linker
Linker Type	Cathepsin-cleavable linker
Antibody-Linker Relation	Cleavable
Structure
	3D MOL			2D MOL
Formula	C59H94Br2N6O20
Isosmiles	BrCC(C(CBr)=NC1=C2)=NC1=CC=C2C(NCCOCCOCCC(N[C@@H](CCCCNC(CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC)=O)C(NC3=CC=C(C=C3)CO)=O)=O)=O
InChI	InChI=1S/C59H94Br2N6O20/c1-73-18-19-77-24-25-79-28-29-81-32-33-83-36-37-85-40-41-87-43-42-86-39-38-84-35-34-82-31-30-80-27-26-78-23-21-74-15-11-56(69)62-13-3-2-4-52(59(72)64-50-8-5-48(47-68)6-9-50)67-57(70)12-16-75-20-22-76-17-14-63-58(71)49-7-10-51-53(44-49)66-55(46-61)54(45-60)65-51/h5-10,44,52,68H,2-4,11-43,45-47H2,1H3,(H,62,69)(H,63,71)(H,64,72)(H,67,70)/t52-/m0/s1
InChIKey	ITISVKVTVPZOLX-MPLRIKRWSA-N
Pharmaceutical Properties	Molecule Weight		1367.231	Polar area		300.86
	Complexity		2106.8602	xlogp Value		3.7107
	Heavy Count		87	Rot Bonds		60
	Hbond acc		22	Hbond Donor		5

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.036 nM	High FRA expression (FRA +++)
Method Description	Use crystal violet analysis to evaluate the in vitro efficacy of the prepared ADCs. Initially screen all MORAb003 ADCs on IGROV1 (FRi (+++)) and SJSA - 1 (FReg (-)) cells.
In Vitro Model	Osteosarcoma	SJSA-1 cells		CVCL_1697
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.383 nM	High FRA expression (FRA +++)
Method Description	Use crystal violet analysis to evaluate the in vitro efficacy of the prepared ADCs. Initially screen all MORAb003 ADCs on IGROV1 (FRi (+++)) and SJSA - 1 (FReg (-)) cells.
In Vitro Model	Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma	IGROV1 cells		CVCL_1304

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	17.3 nM	High FRA expression (FRA +++)
Method Description	Use crystal violet analysis to evaluate the in vitro efficacy of the prepared ADCs. Initially screen all MORAb003 ADCs on IGROV1 (FRi (+++)) and SJSA - 1 (FReg (-)) cells.
In Vitro Model	Osteosarcoma	SJSA-1 cells		CVCL_1697
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 500 nM	High FRA expression (FRA +++)
Method Description	Use crystal violet analysis to evaluate the in vitro efficacy of the prepared ADCs. Initially screen all MORAb003 ADCs on IGROV1 (FRi (+++)) and SJSA - 1 (FReg (-)) cells.
In Vitro Model	Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma	IGROV1 cells		CVCL_1304

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	61.6 nM	High FRA expression (FRA +++)
Method Description	Use crystal violet analysis to evaluate the in vitro efficacy of the prepared ADCs. Initially screen all MORAb003 ADCs on IGROV1 (FRi (+++)) and SJSA - 1 (FReg (-)) cells.
In Vitro Model	Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma	IGROV1 cells		CVCL_1304
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	500 nM	High FRA expression (FRA +++)
Method Description	Use crystal violet analysis to evaluate the in vitro efficacy of the prepared ADCs. Initially screen all MORAb003 ADCs on IGROV1 (FRi (+++)) and SJSA - 1 (FReg (-)) cells.
In Vitro Model	Osteosarcoma	SJSA-1 cells		CVCL_1697

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 100 nM	High FRA expression (FRA +++)
Method Description	Use crystal violet analysis to evaluate the in vitro efficacy of the prepared ADCs. Initially screen all MORAb003 ADCs on IGROV1 (FRi (+++)) and SJSA - 1 (FReg (-)) cells.
In Vitro Model	Osteosarcoma	SJSA-1 cells		CVCL_1697

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 100 nM	High FRA expression (FRA +++)
Method Description	Use crystal violet analysis to evaluate the in vitro efficacy of the prepared ADCs. Initially screen all MORAb003 ADCs on IGROV1 (FRi (+++)) and SJSA - 1 (FReg (-)) cells.
In Vitro Model	Osteosarcoma	SJSA-1 cells		CVCL_1697
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	144 nM	High FRA expression (FRA +++)
Method Description	Use crystal violet analysis to evaluate the in vitro efficacy of the prepared ADCs. Initially screen all MORAb003 ADCs on IGROV1 (FRi (+++)) and SJSA - 1 (FReg (-)) cells.
In Vitro Model	Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma	IGROV1 cells		CVCL_1304

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 500 nM	High FRA expression (FRA +++)
Method Description	Use crystal violet analysis to evaluate the in vitro efficacy of the prepared ADCs. Initially screen all MORAb003 ADCs on IGROV1 (FRi (+++)) and SJSA - 1 (FReg (-)) cells.
In Vitro Model	Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma	IGROV1 cells		CVCL_1304
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	500 nM	High FRA expression (FRA +++)
Method Description	Use crystal violet analysis to evaluate the in vitro efficacy of the prepared ADCs. Initially screen all MORAb003 ADCs on IGROV1 (FRi (+++)) and SJSA - 1 (FReg (-)) cells.
In Vitro Model	Osteosarcoma	SJSA-1 cells		CVCL_1697

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 500 nM	High FRA expression (FRA +++)
Method Description	Use crystal violet analysis to evaluate the in vitro efficacy of the prepared ADCs. Initially screen all MORAb003 ADCs on IGROV1 (FRi (+++)) and SJSA - 1 (FReg (-)) cells.
In Vitro Model	Osteosarcoma	SJSA-1 cells		CVCL_1697

Ref 1	Fan bracket